Divi's Laboratories Limited

NSE DIVISLAB.NS

Divi's Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2024: 10.34%

Divi's Laboratories Limited Return on Assets (ROA) is 10.34% for the year ending March 31, 2024, a -18.13% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Divi's Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2023 was 12.63%, a -42.93% change year over year.
Divi's Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2022 was 22.13%, a 20.18% change year over year.
Divi's Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2021 was 18.42%, a 14.20% change year over year.
Divi's Laboratories Limited Return on Assets (ROA) for the year ending March 31, 2020 was 16.13%, a -4.17% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: DIVISLAB.NS

Divi's Laboratories Limited

CEO	Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
IPO Date	March 12, 2003
Location	India
Headquarters	Divi Towers
Employees	9,741
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Dairy & Milk Drugstores & Retail Pharmacies Fertilizers Non-Alcoholic Beverages Personal Care Plastics

Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

Key trends

Past 5 years